Daylight-PDT With MAL for AK and Photodamaged Skin

This study is a multicenter study investigating the clinical efficacy of repetitive daylight-PDT with MAL compared to cryosurgery in regard to prophylaxis and treatment of AKs in the face. Patients will be randomly allocated to treatment groups. 5 PDT treatment sessions (visits 1-5) will be performed within 18 months. In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5.

Before application of the photosensitizer, an organic sunscreen (Actinica® lotion, LSF 50+) without mineral filters will be applied In the entire face.

After an absorption time of approximately 15 minutes and before applying MAL (Metvix®), the surface of the AK lesions will be prepared gently with a curette or a scalpel to remove scales and crusts and roughen the surface of the AK-lesions. This is to facilitate penetration of the cream and light to the AK lesions.

After lesion preparation, MAL (Metvix®) will be uniformly applied on the whole face in a thin layer.

Within 30 min after MAL application the patients go outside and expose themselves for 2 hours to daylight. Daylight-PDT can be performed from March until October, during non-rainy weather with an outdoor temperature of at least 10° Celsius. Daylight exposure must start at least 3 hours before sunset.

At the end of the exposure, residual photosensitizer is washed off and the patients spend the rest of the day indoors.

Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.

Inclusion criteria

• Written informed consent has been signed prior to or at Screening Visit
• Male and female patients with Fitzpatrick skin type I-IV
• Age > 40 years
• Negative pregnancy test in women of childbearing age
• Women in child-bearing age using highly efficient contraceptive methods (<1% failure rate per year)
• Clinical diagnosis of actinic keratosis (AK)
• A minimum of five non-hyperkeratotic, non-pigmented AK lesions in the face.
• Glogau Photodamage Classification Type II (moderate) - IV (severe)

Exclusion criteria

• Diagnosis of porphyria
• Hyperkeratotic or pigmented AK in the face
• Malignant skin tumors in the face or on the capillitium, requiring treatment
• Patients with clinically relevant suppression of the immune system (e.g. drug induced, infection) or organ transplant patients
• Pregnancy or lactation
• Planned aesthetic treatments in the face in the next 24 months (filler, peeling, botulinumtoxin, skin resurfacing)
• Known intolerance or allergy to MAL or to any other ingredient of Metvix® 160mg/g cream
• Known intolerance to Actinica® lotion
• Photosensitivity
• Suspected lack of compliance (e.g. due to dementia)
• Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
• Concomitant UV-phototherapy
• Skin diseases that might interfere with response evaluation of study treatment
• Skin sun sensitivity type V or VI according to Fitzpatrick
• PDT in the face during 6 months preceding study treatment
• Non-permitted medication:
• Topical treatment in the face during 4 weeks preceding study treatment with diclofenac, hydrochinone, peeling, 5-FU, ingenolmebutate, retinoids, podophyllin, azelaic acid, imiquimod or other agents, that could interfere with the evaluation of the efficacy of the study treatment, according to the investigator.
• Systemic treatment with retinoids
• Conditions that might interfere with the ability to understand the study and thus give written informed consent
• Rejuvenating treatments of the face during 3 months preceding study treatment, including filler, botulinumtoxin and IPL